Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
暂无分享,去创建一个
S. Groshen | J. Maris | K. Matthay | Y. Mossé | Julie R. Park | K. Goldsmith | A. Marachelian | K. Kayser | Esther R Berko | M. Chioda | M. Granger | G. Peltz | H. Thurm | Joseph Chen | Suzy Ghazarian